Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, Wolfgang Boehmerle, Petra Huehnchen, Matthias Endres, Raphael Mohr, Annette Compter, Christian U Blank, Tim Hagenacker, Friedegund Meier, Lydia Reinhardt, Anja Gesierich, Martin Salzmann, Jessica C Hassel, Selma Ugurel, Lisa Zimmer, Patricia Banks, Lavinia Spain, Jennifer A Soon, Tomohiro Enokida, Makoto Tahara, Katharina C Kähler, Ruth Seggewiss-Bernhardt, Catriona Harvey, Georgina V Long, Florian Schöberl, Louisa von Baumgarten, Thomas Hundsberger, Max Schlaak, Lars E French, Samuel Knauss, Lucie M Heinzerling
Over the past decade, cancer immunotherapy with immune checkpoint inhibitors (ICIs) has significantly improved the outcome of many malignancies. However, with the broad use of ICIs, neurological immune related adverse events (irAE) are increasingly recognized. ICI-induced encephalitis (ICI-iE) is a particularly severe irAE, often leading to treatment termination, long-term sequalae or death. Despite its high morbidity and mortality, data on clinical features and diagnostic criteria are limited. We aimed to define clinical, radiologic and laboratory characteristics of ICI-iE and identify factors that discriminate it from anti-leucine-rich glioma-inactivated (anti-LGI)-1 encephalitis and herpes simplex virus (HSV)-1 encephalitis - two alternative causes of encephalitis - to increase the awareness of ICI-iE and improve its diagnosis and management...
December 2022: Data in Brief